Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
177Lu-FAP-2286 is a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP. FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach radioactive isotopes for imaging and therapeutic use.
Lead Product(s): 177Lu-FAP-2286
Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Novartis Innovative Therapies
Deal Size: $680.7 million Upfront Cash: $50.0 million
Deal Type: Divestment December 12, 2022
Details:
Rubraca(Rucaparib) is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents.
Lead Product(s): Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
177Lu-FAP-2286 consists of two functional elements; a targeting peptide that binds to FAP and a site that can be used to attach medical radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use.
Lead Product(s): 177Lu-FAP-2286
Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Isotopia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2022
Details:
The ATHENA-MONO trial met its primary endpoint, showing Rubraca (rucaparib) monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients randomized.
Lead Product(s): Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
Rubraca (rucaparib) is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents.
Lead Product(s): Rucaparib Camsylate,Nivolumab
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
Overall, in nine patients treated in the first two dose cohorts,177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in one patient.
Lead Product(s): 177Lu-FAP-2286
Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
The ATHENA-MONO trial met its primary endpoint, showing Rubraca (rucaparib) monotherapy versus placebo improved progression-free survival (PFS) by investigator assessment in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT).
Lead Product(s): Rucaparib Camsylate,Nivolumab
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents.
Lead Product(s): Rucaparib Camsylate,Nivolumab
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
In non-clinical data analysis, FAP-2286 demonstrated potent activity for human fibroblast activation protein by biochemical and cell-based assays, 177Lu-FAP-2286 showed longer tumor retention, resulting in greater tumor inhibition as compared to 177LuFAPI-46.
Lead Product(s): 177Lu-FAP-2286
Therapeutic Area: Oncology Product Name: 177Lu-FAP-2286
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Heidelberg
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents.
Lead Product(s): Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: Rubraca
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022